Forms will be updated on a quarterly basis for the monthly dividends.

Dr. Rosenwald has almost 25 years of biotechnology entrepreneurship experience, including founding and recapitalizing biotechnology and life sciences companies. Dr. Rosenwald is Cyprium’s Executive Chairman and Fortress Biotech’s Chairman and CEO.

Cyprium Therapeutics focuses on developing therapies for Menkes disease and related copper metabolism disorders. In March 2017, it entered a CRADA with NICHD to advance the clinical development of CUTX-101.

March 2026 :: Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

The Privacy Policy explains what information the Site may collect, how it may be used or shared, how it is safeguarded, and how users may access and control its use in marketing communications and activities.

Fortress Biotech secures FDA approval for **ZYCUBO®**, a treatment for **Menkes disease in pediatric patients**. The company’s subsidiary, **Cyprium**, then closes a **$205 million private placement (PRV) sale** in the first quarter of 2026. The approval marks a milestone for the rare disease therapy, while the funding supports further development and commercialization efforts.

May 2026pharmanow.liveNews article

Cyprium Therapeutics, a subsidiary of Fortress Biotech, agrees to sell its Rare Pediatric Disease Priority Review Voucher (PRV) in a deal expected to generate **$205 million** in gross proceeds. The transaction involves a definitive asset purchase agreement, marking a significant financial milestone for the biotech subsidiary. The PRV, a regulatory expediting tool for rare pediatric disease treatments, is the focus of the sale.

Feb 2026BioSpaceNews article

Fortress Biotech and Cyprium Therapeutics receive FDA acceptance of their resubmitted New Drug Application (NDA) for **CUTX-101**, a treatment for **pediatric Menkes disease**. The agency sets a new **PDUFA action date of January 14, 2026**, marking progress in regulatory review for the therapy.

Dec 2025pharmanow.liveNews article

Fortress Biotech and Cyprium Therapeutics receive FDA acceptance for the resubmitted New Drug Application (NDA) of **CUTX-101 (copper histidinate)**, a treatment for **Menkes disease in pediatric patients**. The resubmission is classified as a **Class 1**, setting a new **PDUFA target action date of January 14, 2026**. The companies now await regulatory review for potential approval.

Dec 2025MarketScreenerNews article